The majority of women with early-stage breast cancer have a Low Risk of cancer relapse based on genomic testing and may safely avoid chemotherapy.1 So how do you know if chemotherapy will benefit you? The MammaPrint 70-Gene Test is currently the only FDA-cleared test for risk of disease recurrence within five years for women of all ages. The test provides a personalized, binary result so you can know if you are Low Risk for cancer relapse – and not likely to show a significant benefit from chemotherapy.
1. Cardoso F, van’t Veer LJ, Bogaerts J et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med. 2016; 375:717-29.
LOCATE A PHYSICIAN >>